Zentalis Pharmaceuticals, Inc. (ZNTL) Institutional Ownership

Ownership Summary

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) showed up in the 13F filings of 84 institutional investors as of December 2025.

• Their combined ownership stood at 56.3% of outstanding shares in December 2025, down from 76.2% in September 2025.
• Their total shares held in ZNTL increased 10.64% quarter over quarter, and separately, investors owning Zentalis Pharmaceuticals decreased 40.0% from a year ago.
• Of these 84 funds, 37 grew their exposure to Zentalis Pharmaceuticals, 32 cut back, and 15 maintained positions.
• The aggregate institutional position in Zentalis Pharmaceuticals amounted to 40.6Mn shares as of December 2025, up by 3.91Mn shares quarter on quarter, and down 25.73Mn shares year over year.
• 5AM Venture Management, LLC leads ownership in ZNTL with 3.95Mn shares as of December 31, 2025, equal to 5.47% of outstanding shares.
• The biggest buyers of Zentalis Pharmaceuticals for the quarter ending December 2025 included Squadron Capital Management LLC (3.63Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.31Mn), TWO SIGMA INVESTMENTS, LP (1.49Mn), Qube Research & Technologies Ltd (619.64K), MILLENNIUM MANAGEMENT LLC (616.69K).
• Top sellers of ZNTL stock for the quarter ending December 2025 included Opaleye Management Inc. (1.39Mn), RENAISSANCE TECHNOLOGIES LLC (945.6K), GSA CAPITAL PARTNERS LLP (549.17K), UBS Group AG (518.89K), Morgan Stanley (453.45K).
• Business Quant data shows the 10 biggest positions in Zentalis Pharmaceuticals as of December 2025 are held by 5AM Venture Management, LLC (3.95Mn), Squadron Capital Management LLC (3.63Mn), TWO SIGMA INVESTMENTS, LP (2.96Mn), ACADIAN ASSET MANAGEMENT LLC (2.85Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.31Mn), RENAISSANCE TECHNOLOGIES LLC (1.94Mn), CITADEL ADVISORS LLC (1.73Mn), D. E. Shaw & Co., Inc. (1.48Mn), Opaleye Management Inc. (1.41Mn), Decheng Capital LLC (1.32Mn).